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Background: Osteoclasts are primarily responsible for bone resorption. In many pathological bone diseases
including osteoporosis and rheumatoid arthritis, osteoclasts are excessively activated. Thus, controlling of osteoclasts
would be an effective therapeutic strategy for the treatment of excessive bone loss. The stem of Spatholobus
suberectus has been widely used in traditional medicine to treat blood stasis syndrome and arthritis in Asia. In the
present study, we investigated the effects and action mechanism of water extract of the stem of Spatholobus
suberectus (WESS) on osteoclast differentiation and function.
Methods: The effect of WESS on osteoclast differentiation was evaluated by counting tartrate resistant acid
phosphatase-positive multinucleated cells in bone marrow-derived macrophages system and murine bone marrow
cell-osteoblast coculture system. Bone resorption activity of mature osteoclast was examined on a calcium
phosphate-coated plate. Actin ring structure of osteoclasts was detected fluorescently by staining for F-actin.
Activation of signaling pathways and induction of transcription factors required for osteoclastogenesis were
investigated by real-time PCR and Western blotting.
Results: WESS effectively inhibited osteoclast differentiation from its precursors. The inhibitory effect of WESS on
osteoclast differentiation was due to the suppression of osteoclastogenic transcription factors, c-Fos and nuclear
factor of activated T cells cytoplasmic 1 expression, via preventing receptor activator of nuclear factor-κB ligand-
induced early signaling pathways and decreasing c-Fos protein level in osteoclast precursors. Furthermore, WESS
suppressed bone resorption activity of osteoclasts by disrupting actin ring structure.
Conclusions: This study demonstrated that WESS inhibits osteoclast differentiation and function. These results
suggest that WESS has a potential for treating pathological bone diseases caused by excessive bone resorption.
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Bone remodeling is a coupled process consisting of osteo-
clastic bone resorption followed by osteoblastic bone for-
mation throughout life [1]. It is necessary to repair
damaged bone and to maintain mineral homeostasis. Pro-
gressive and excessive bone resorption by osteoclasts than
bone formation causes an imbalance of bone remodeling
which is characterized in several pathological bone dis-
eases including osteoporosis, Paget’s disease, and rheuma-
toid arthritis [1].
Osteoclasts are exclusive bone-resorbing multinucleated
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reproduction in any medium, provided the orof hematopoietic cells belonging to the monocyte/macro-
phage lineage [1,2]. When attached to bone matrix,
multinucleated osteoclasts polarize their membrane to
bone and secrete protons and lytic enzymes such as ca-
thepsin K into the resorption lacuna surrounded by a tight
sealing zone [1]. The sealing zone, a characteristic feature
of functional osteoclast, isolates the resorptive microenvir-
onment from the general extracellular space. It contains
ring-like structures called actin ring consisting of F-actin
dots [3].
Receptor activator of NF-κB ligand (RANKL) is the
key cytokine that stimulates entire processes for the de-
velopment of bone-resorbing osteoclasts: commitment,
fusion, and activation [2,4]. RANKL is produced by sev-
eral cell types including osteoblasts and mineralizedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Upon binding to its receptor RANK on the cell surface of
osteoclast precursors, RANKL induces the recruitment of
adaptor molecules such as tumor necrosis factor receptor-
associated factor 6, which activates multiple downstream
signaling molecules including mitogen-activated protein
kinases (MAPKs) and NF-κB. These signaling pathways in
turn ultimately lead to induction and activation of tran-
scription factors required for osteoclast differentiation and
activation [6]. Those transcription factors include c-Fos
and nuclear factor of activated T-cells cytoplasmic 1
(NFATc1). c-Fos, a component of activator protein-1, is in-
duced by RANKL stimulation in osteoclast precursors,
and mice lacking c-Fos are osteopetrotic due to impaired
osteoclast development [7,8]. NFATc1 functions as a mas-
ter transcription factor for osteoclast differentiation, and
its induction is dependent on c-Fos [9,10].
There is a growing interest in the utilization of medicinal
plants for prevention and treatment of bone disorders in-
cluding osteoporosis [11]. To evaluate bone-protective
potential of traditional Korean herbal medicines, we inves-
tigated the effects of water extracts of 150 herbal medicines
on RANKL-induced osteoclast differentiation. Among
them, the stem of Spatholobus suberectus showed relatively
strong inhibitory activity against osteoclast differentiation
without adversely affecting cell viability. In addition, the
stem of S. suberectus, known as Ji Xue Teng in China
and Gye-Hyeol-Deung in Korea, has been used to treat
anemia, menstrual abnormalities, and arthritis in Asia [12].
It has been reported that the extracts of the stem of S.
suberectus exhibit diverse biological functions including
hematopoietic-supportive effects [13], anti-platelet effects
[14], anti-inflammatory activities [15], and antioxidant ac-
tivities [15,16], and anti-rheumatic effects [17,18]. However,
to date the direct effects of S. suberectus on bone metabol-
ism have not been studied. In the present study, we ex-
plored the anti-osteoclastogenic effect of water extract of




The dried stem of S. suberectus was purchased from
Yeongcheon herb (Yeongcheon, Korea). α-modified min-
imal essential medium (α-MEM), fetal bovine serum (FBS),
BCA protein assay kit, and SuperSignal West Femto Max-
imum Sensitivity Substrate were purchased from Thermo
Fisher Scientific Inc. (Rockford, IL, USA). Cell Counting
Kit-8 was obtained from Dojindo Molecular Technologies
Inc. (Tokyo, Japan). RNA-spin total RNA extraction kit,
AccuPower RT-PreMix, and AccuPower GreenStar QPCR
Master Mix were obtained from Bioneer (Daejeon, Korea).
1α,25-dihydroxyvitaminD3 (VitD3), p-nitrophenyl phos-
phate, and phalloidin-TRITC were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies specific for
phospho-ERK1/2 (thr202/Tyr204), ERK, phospho-JNK1/2
(Thr183/Tyr185), JNK, phospho-p38 (Thr180/Tyr182), p38,
phospho-p65 (Ser536), p65, phospho-IκBα (Ser32), and
IκBα were from Cell Singling Technology (Danvers,
MA, USA). Antibodies against c-Fos, NFATc1, β-actin,
and GAPDH were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). M-CSF and RANKL were
kindly provided by Dr. Yongwon Choi (University of
Pennsylvania School of Medicine).
Preparation of WESS
A voucher specimen of S. suberectus (No. E188) was de-
posited in the herbal bank of KM-Based Herbal Drug
Research Group, Korea Institute of Oriental Medicine.
The dried stem of S. suberectus (50 g) was boiled for 3 h
in 1 L of distilled water (DW). After filtration using test-
ing sieves (150 μm) (Retsch, Haan, Germany), the ex-
tract was lyophilized and stored at 4°C before use. To
prepare WESS, the lyophilized powder (yield: 7.35%) was
re-suspended in distilled water, centrifuged at 10,000 × g
for 5 min, and filtered through a 0.2 μm sterile filter.
Animals
5-week-old male ICR mice (Orient Bio Inc., Seoul, Korea)
were housed under constant environmental conditions (22
± 1°C, 55 ± 10% humidity, and 12 h light/dark cycle) with
free access to a standard animal diet and tap water. Bone
marrow cells were collected from the tibias and femurs of
male mice, after acclimatization for 1 week. Newborn ICR
mice were purchased from Orient Bio Inc. for preparation
of mouse calvarial osteoblasts. All animal procedures
were performed according to the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health. The experimental protocols were approved by
the Institutional Animal Care and Use Committee at
Korea Institute of Oriental Medicine (Reference number:
11-125 and 12-004).
Cell culture and osteoclast differentiation
Bone marrow-derived macrophages (BMMs) were derived
from mouse bone marrow cells and cultured in α-MEM
complete medium containing 10% FBS and antibiotics (100
U/ml penicillin and 100 μg/ml streptomycin) in the pres-
ence of M-CSF (60 ng/ml) as described previously [19].
Cell viability of BMMs was determined using Cell Counting
Kit 8, after 2 days of BMMs culture (1 × 104 cells/well in a
96-well plate) with WESS and M-CSF (60 ng/ml). To
differentiate BMMs into osteoclasts, BMMs (1 × 104 cells/
well) were cultured with M-CSF (60 ng/ml) and RANKL
(100 ng/ml) for 4 days in 96-well plates. Mouse calvarial
osteoblasts were obtained from calvariae of newborn
ICR mice by enzymatic digestion as described previously
[19]. For osteoclast differentiation from the coculture of
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105 cells/well) and osteoblasts (2 × 104 cells/well) were
cocultured with VitD3 (10 nM) in 48-well tissue culture
plates for 6 days. All cultures were replenished with fresh
medium on day 3.
For total tartrate-resistant acid phosphatase (TRAP) ac-
tivity assay, cells were fixed in 10% neutral buffered forma-
lin for 10 min, permeabilized with 0.1% Triton X-100
in PBS, and incubated with p-nitrophenyl phosphate as
substrate according to the manufacturer’s instructions
(Sigma-Aldrich) in a TRAP assay buffer (50 mM sodium
tartrate and 0.12 M sodium acetate, pH 5.2). After 10 min
of incubation at 37°C, the reaction was stopped with 1 M
NaOH, and the absorbance was measured at 405 nm using
a spectrophotometer. TRAP staining was carried out using
Naphthol AS-MX phosphate and Fast Red Violet LB
according to the protocol described in BD Biosciences
Technical Bulletin #445. TRAP-positive multinucleated
cells (TRAP(+)MNC) containing more than three nuclei
were counted as osteoclasts.
Retroviral gene transduction
Retrovirus packaging and BMM infection by using retro-
viral vectors pMX-IRES-green fluorescent protein (GFP)
and pMX-constitutively active (CA)-NFATc1-IRES-GFP
were performed as described previously [19]. BMMs
infected with the retroviruses were further cultured in the
presence of M-CSF (60 ng/ml) for 1 day and then treated
as indicated. Ectopic expression of each construct was
detected by a fluorescence microscope (Olympus IX53
inverted microscope), and cells were stained for TRAP.
Real-time quantitative PCR (QPCR)
To evaluate mRNA levels of RANKL and OPG, osteoblasts
(3 × 105 cells/well in a 6-well plate) were pre-incubated
with WESS for 3 h and stimulated with VitD3 for 24 h. To
evaluate mRNA levels of NFATc1 and c-Fos in BMMs,
BMMs (4 × 105 cells/well in a 6-well plate) were pre-
incubated with WESS for 3 h in the presence of M-CSF
(60 ng/ml) and further cultured with RANKL (100 ng/ml)
for indicated times. Total RNA was isolated with an RNA-
spin total RNA Extraction Kit according to the manufac-
turer’s protocol. cDNA was synthesized from 1 μg of total
RNA in AccuPower RT-PreMix according to the manufac-
turer’s protocol. SYBR green-based QPCR amplification
was performed using cDNA diluted to 1:3, 10 pmol of
primers, and AccuPower GreenStar QPCR Master Mix in
the Applied Biosystems 7500 Real-Time PCR System (Ap-
plied Biosystems, Foster City, CA, USA). The PCR reaction
consisted of 40 cycles of 94°C for 20 s and 60°C for 40 s.
All reactions were run in triplicate, and data were analyzed
using the 2-ΔΔCT method. HPRT was used as an internal
control to normalize RNA amount. The primer sequences
used were described previously [19].Western blot analysis
BMMs treated as indicated were washed twice with ice-
cold PBS and lysed in a protein extraction buffer containing
20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% NP-40, 0.1% SDS, and protease and phosphatase
inhibitor cocktails (Roche Applied Science, Indianapolis,
IN, USA) at 4°C. Total cell lysates were obtained by centri-
fugation at 10,000 × g for 15 min at 4°C. Protein concen-
tration of lysates was determined with a BCA Protein
Assay Kit. Protein samples (30 μg) were subjected to SDS-
polyacrylamide gel electrophoresis and transferred to
polyvinylidende fluoride membranes. Membranes were
blocked with blocking buffer, 5% non-fat dry milk in TBST
(10 mM Tris-HCl [pH 7.5], 150 mM NaCl, and 0.1%
Tween 20), for 1 h at room temperature, probed with the
indicated primary antibodies (1/1000 dilution) overnight at
4°C, and then washed with TBST three times for 10 min
each. Afterward, membranes were incubated with horserad-
ish peroxidase-conjugated secondary antibodies (1/4000 di-
lution) for 1 h at room temperature and washed with TBST
three times. Chemiluminescent signals were detected on a
LAS-4000 Luminescent Image Analyzer (Fuji Photo Film
Co., Tokyo, Japan) with SuperSignal West Femto Max-
imum Sensitivity Substrate.
Resorption pit assay
Mature osteoclasts were generated by coculturing of
mouse bone marrow cells and osteoblasts with VitD3 (10
nM) on collagen gels for 6 days. The generated osteoclasts
were replated on an Osteo Assay Surface plate (Corning,
NY, USA), allowed to settle for 2 h, and then incubated
with different concentrations of WESS for 24 h. After the
incubation period, osteoclasts were visualized by TRAP
staining. Resorption pits were photographed and analyzed
by using Image J software, after removing cells by using
sodium hypochlorite bleach.
Actin ring formation assay
Osteoclasts were generated from BMM culture with M-
CSF and RANKL on tissue culture plates as described
above and then treated with different concentrations of
WESS for 30 min. Cells were washed with PBS, fixed in
10% neutral buffered formalin for 10 min, permeabilized
with 0.1% Triton X-100 in PBS for 5 min, and incubated
with phalloidin-TRITC (0.2 μg/ml in PBS) for 15 min.
After washing three times with PBS, F-actin stained with
phalloidin-TRITC was photographed using a fluores-
cence microscope (Olympus IX53 inverted microscope).
Statistical analysis
All quantitative data are presented as mean ± SD of three
independent experiments. Statistical difference was de-
termined by Student’s t test for two-group comparisons
or by one-way analysis of variance followed by Tukey’s
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less than 0.05 were considered significant.
Results
Effect of WESS on osteoclast differentiation in bone
marrow cell-osteoblast coculture
It has been known that osteoblasts control osteoclast differ-
entiation by expressing RANKL and its decoy receptor
osteoprotegerin (OPG). Many osteoclastogenic factors
such as VitD3, IL-1, and PTH stimulate osteoclast differen-
tiation by increasing the ratio of RANKL to OPG [1]. To
investigate whether WESS affects the ability of osteoblasts
to support osteoclast differentiation, we tested in bone mar-
row cell-osteoblast coculture system. Treatment of the
coculture with VitD3 for 6 days induced TRAP-positive
multinucleated osteoclasts, which was dramatically in-
hibited by WESS in a dose-dependent manner (Figure 1A
and B). We next examined whether WESS could regulate
the expression of RANKL and OPG in osteoblasts. VitD3
increased RANKL mRNA levels and decreased OPG
mRNA levels. Pretreatment with 25 μg/ml of WESS, a suffi-
cient concentration to inhibit osteoclast differentiation, did
not affect RANKL and OPG mRNA expression in basal or
VitD3-stimulated osteoblasts (Figure 1C).
Effect of WESS on RANKL-induced osteoclast differentiation
Because the inhibitory effect of WESS on osteoclast for-
mation in coculture was not due to changes in RANKLFigure 1 Inhibitory effect of WESS on osteoclast differentiation in bon
calvarial osteoblasts were cocultured with vehicle (DW) or WESS in the pre
pictures of TRAP staining are shown at 100× magnification. (B) The numbe
three or more nuclei were counted. Data represents mean ± SD of three in
(C) Osteoblasts were pre-incubated with vehicle or WESS (25 μg/ml) for 3 h
levels were analyzed by QPCR.and OPG expression in osteoblasts, we next investigated
the possibility that WESS inhibits osteoclast differenti-
ation via directly acting on osteoclast precursor cells.
When BMMs (osteoclast precursors) were cultured with
RANKL in the presence of M-CSF for 4 days, numerous
TRAP-positive multinucleated osteoclasts were gener-
ated. WESS inhibited RANKL-induced TRAP activity
and osteoclast formation in a dose-dependent manner
(Figure 2A-C). Consistent with the results of coculture
experiment, a strong inhibition was observed at 25 μg/ml
concentration of WESS. The inhibitory effect of WESS was
not due to cellular toxicity. Rather, it increased cell viability
of BMMs at concentrations of 5-50 μg/ml. Thus, 25 μg/ml
of WESS was chosen for the subsequent experiments to in-
vestigate the anti-osteoclastogenic effect of WESS.
Effect of WESS on RANKL-induced c-Fos and NFATc1
expression
To address the inhibitory mechanism of WESS on
RANKL-induced osteoclastogenesis, we explored the ef-
fect of WESS on the expression of c-Fos and NFATc1, key
transcription factors for osteoclast differentiation [8,9].
Stimulation of BMMs with RANKL increased c-Fos
mRNA and protein levels reaching a peak at day 1,
followed by NFATc1 induction. In the absence of RANKL,
WESS dramatically decreased c-Fos protein but not
mRNA level. In addition, WESS abrogated RANKL-
induced c-Fos and NFATc1 induction (Figure 3A and B).e marrow cell-osteoblast coculture. Mouse bone marrow cells and
sence of VitD3 (10 nM) for 6 days. (A) Representative microscopic
r of TRAP-positive multinucleated osteoclasts (TRAP(+)MNC) containing
dependent experiments. cP < 0.001 vs. vehicle-treated control group.
and stimulated with VitD3 (10 nM) for 24 h. RANKL and OPG mRNA
Figure 2 Inhibitory effect of WESS on osteoclast differentiation in BMMs. BMMs were cultured with vehicle or WESS in the presence of
M-CSF (60 ng/ml) and RANKL (100 ng/ml) for 4 days. (A) Representative microscopic pictures of TRAP staining. (B) Total cellular TRAP activity.
(C) The number of TRAP(+)MNC containing three or more nuclei. (D) Effect of WESS on the viability of BMMs in the presence of M-CSF
(60 ng/ml). All bar graphs represent mean ± SD of three independent experiments. bP < 0.01, cP < 0.001 vs. control group.
Figure 3 Inhibitory effect of WESS on RANKL-induced c-Fos and NFATc1 expression in BMMs. BMMs were pre-incubated with vehicle or
WESS (25 μg/ml) for 3 h and further cultured in the presence of M-CSF (60 ng/ml) and RANKL (100 ng/ml) for 4 days. Total RNA and cell lysates
were obtained at the indicated days. (A) c-Fos and NFATc1 mRNA levels were analyzed by QPCR. aP < 0.05, bP < 0.01, cP < 0.001 vs. vehicle-
treated control group. (B) Total cell lysates were subjected to Western blot analysis with antibodies specific for c-Fos and NFATc1. GAPDH was
used as a loading control. (C) BMMs infected with retroviruses expressing either pMX-IRES-GFP (pMX) or pMX-CA-NFATc1-IRES-GFP (pMX-CA-
NFATc1) were cultured with vehicle or WESS (25 μg/ml) in the presence of M-CSF (60 ng/ml) and RANKL (100 ng/ml) for 4 days. The number of
TRAP(+)MNC containing more than three nuclei with GFP expression were counted. Data represents mean ± SD of three independent
experiments. cP < 0.001 vs. vehicle-treated control group.
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was overcome by ectopic expression of CA-NFATc1 in
BMMs (Figure 3C).
Effect of WESS on RANKL-induced early signaling
pathways
To gain more insights into the inhibitory mechanism
of WESS on RANKL-induced osteoclastogenesis, we ex-
plored the effect of WESS on RANKL-induced activation
of MAPKs and NF-κB. These signaling pathways are in-
volved in RANKL-induced c-Fos expression and osteoclast
differentiation [7,20-22]. WESS suppressed RANKL-
induced activation of JNK but not ERK and p38 MAPKs,
assessed by Western blotting with phosphorylated form-
specific antibodies (Figure 4). It also abrogated RANKL-
induced p65 phosphorylation (Ser536) without affecting
IκBα phosphorylation and degradation (Figure 4).
Effect of WESS on bone resorption activity
Bone resorption is the unique function of osteoclasts.
To investigate whether WESS affects bone resorptionFigure 4 Inhibitory effect of WESS on RANKL-induced
activation of JNK and p65 in BMMs. BMMs were pre-treated with
vehicle or WESS (25 μg/ml) for 3 h and stimulated with RANKL
(100 ng/ml). Total cell lysates were prepared at the indicated time
points and then subjected to Western blot analysis using the
indicated antibodies. β-actin was used as a loading control.activity of osteoclasts, mature osteoclasts were cultured
on a plate coated with an inorganic crystalline calcium
phosphate designed to mimic bone mineral. After 24 h
of culture, numerous resorption pits by osteoclasts were
observed on the plate in vehicle-treated control group.
WESS dose-dependently reduced bone resorption area
(Figure 5A and C) without affecting the number of oste-
oclasts (Figure 5A and B), indicating that WESS inhibits
bone resorption activity of osteoclasts. The bone resorp-
tion function of osteoclasts depends on dynamic regula-
tion of the actin cytoskeleton. Actin ring structure is a
characteristic cytoskeletal feature of functional osteoclasts
[3]. Therefore, we next examined whether WESS affects
actin ring structure of mature osteoclasts. In mature oste-
oclasts on tissue culture plates, F-actin was arranged into
a ring-like structure (actin ring) at the cell periphery.
Treatment of mature osteoclasts with WESS caused both
shrinkage of osteoclasts and disruption of actin ring struc-
ture in a dose-dependent manner (Figure 6).
Discussion
The stem of S. suberectus has been used for the treat-
ment of inflammation and arthritis in Asia. Although
WESS was shown to exhibit beneficial effects on
collagen-induced arthritis by its immunomodulatory ef-
fects [18], its direct action on bone metabolism remains
unknown. Here we have demonstrated for the first time
that WESS inhibits osteoclast differentiation and bone
resorption function.
WESS inhibited VitD3-induced osteoclast differenti-
ation in the coculture system without affecting VitD3-in-
duced changes in RANKL and OPG expression in
osteoblasts. It also inhibited RANKL-induced osteoclast
differentiation in BMM culture with similar potency. We
found that WESS inhibits RANKL-induced c-Fos and
NFATc1 induction in BMMs, and ectopic expression of
CA-NFATc1 in BMMs reverses the inhibitory effect of
WESS on osteoclast differentiation. These results sug-
gest that the anti-osteoclastogenic effect of WESS is
mainly caused by suppressing RANK signaling to induce
c-Fos and NFATc1 expression in osteoclast precursors.
In studies on mechanisms underlying the inhibitory
action of WESS, we found that WESS inhibits RANKL-
induced JNK activation without affecting ERK and p38 acti-
vation in osteoclast precursors. Previous experiments using
interferences of MKK7, JNK, and c-Jun with dominant-
negative and small interfering RNA knockdown approaches
have demonstrated that the sequential activation of the
MKK7-JNK-c-Jun signaling pathway mediates RANKL-
induced NFATc1 expression and osteoclastogenesis [23]. In
addition, treatment with SP600125, a specific JNK inhibi-
tor, also impaired c-Fos and NFATc1 expression as well as
osteoclastogenesis in response to RANKL [22]. Thus,
these observations suggest that WESS interferes with
Figure 5 Inhibitory effect of WESS on bone resorption activity of mature osteoclasts. Mature osteoclasts generated on collagen gels were
replated on an Osteo Assay Surface plate and cultured with vehicle or WESS for 24 h. (A) Representative microscopic pictures of TRAP staining
(upper panel) and resorption pits (down panel). (B) The number of TRAP(+)MNC containing three or more nuclei. (C) Relative resorption area.
Data represents mean ± SD of three independent experiments. cP < 0.001 vs. vehicle-treated controls.
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RANKL-induced JNK activation, thereby abrogating
osteoclastogenesis.
Genetic studies have demonstrated that NF-κB signaling
pathway plays a crucial role in osteoclastogenesis [6]. It
has been suggested that NF-κB functions upstream of
c-Fos during RANKL-induced osteoclastogenesis [7]. The
classic NF-κB signaling pathway involves activation of the
IκB kinase (IKK) complex that leads phosphorylation andFigure 6 Inhibitory effect of WESS on actin ring structure of mature o
30 min. Osteoclasts were fixed, and F-actin was visualized by fluorescencedegradation of IκBα, allowing nuclear translocation of NF-
κB complexes containing the p50 and p65 subunits. The
transcriptional activity of NF-κB can be controlled by
various post-translational modifications, including p65
phosphorylation and acetylation [24]. In the present
study, WESS did not affect RANKL-induced IκBα phos-
phorylation and degradation. However, WESS abrogated
RANKL-induced p65 phosphorylation on Ser536. The
phosphorylation of p65 on Ser536 in the transactivationsteoclasts. Mature osteoclasts were treated with vehicle or WESS for
microscope with phalloidin-TRITC staining.
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activity in response to inflammatory stimuli [25-27]. In
addition, it has been reported that transforming growth
factor-beta-activated kinase 1-MKK6-p38 signaling path-
way participates to RANKL-induced NF-κB activation and
osteoclastogenesis by stimulating p65 phosphorylation on
Ser536 [28]. Therefore, our study suggests that the inhibi-
tory effect of WESS on NF-κB activation may contribute
to its anti-osteoclastogenic action. Given that IKKβ medi-
ates RANKL-induced IκBα phosphorylation and degrad-
ation in osteoclast precursors [29], our findings suggest
that WESS might target IKKβ-independent Ser536 protein
kinases that include IKKα, IKKε, NF-κB activating kinase,
bruton’s tyrosine kinase, protein kinase D3, and p38
[25-28,30].
In addition to inhibition of RANKL-induced c-Fos mRNA
and protein expression, WESS dramatically decreased
c-Fos protein level without negatively affecting c-Fos
mRNA level in the absence of RANKL. IFN-β has been
shown to inhibit c-Fos protein synthesis via activation
of IFN-stimulated transcriptional factor 3 in osteoclast
precursors [31]. However, the molecular mechanisms
involved in the reduction of c-Fos protein expression by
WESS remain to be elucidated.
Besides inhibiting osteoclast differentiation, WESS de-
creased bone resorption activity of mature osteoclasts in
a dose-dependent manner, which was accompanied by a
rapid disruption of actin ring structure in mature osteo-
clasts. Antioxidants such as N-acetyl-L-cysteine and gluta-
thione were shown to inhibit actin ring formation and
bone resorption activity of osteoclasts [32]. In contrast,
reactive oxygen species showed the opposite effects
[32,33]. Notably, WESS was found to exhibit the highest
antioxidant activity among 45 Chinese herbs that regu-
late blood circulation [16]. Given the pivotal role of
actin ring structure in bone resorption activity of osteo-
clasts [3], these observations collectively suggest that
the strong antioxidant activity of WESS might contrib-
ute to its anti-resorptive activity by disrupting actin ring
structure.
Chemical analyses have found that ethanol and metha-
nol extracts of the dried stems of S. suberectus contain
several flavonoids including genistein, daidzein, and
isoliquiritigenin [34,35]. Although there is a lack of in-
formation on chemical compounds contained in WESS,
WESS was shown to have high contents of total pheno-
lics (24.11 GAE mg/g) and total flavonoids (165.16 QE
mg/g) [15]. Flavonoids possess powerful antioxidant
properties due to their polyphenolic chemical structure
[36]. In addition, some flavonoids such as genistein,
daidzein, and epigallocatechin-3-gallate have been shown
to inhibit osteoclastogenesis by suppressing c-Fos ex-
pression [22,37]. Therefore, it is likely that certain com-
ponents of WESS, possibly flavonoids, exert potentinhibitory effects on osteoclast differentiation and func-
tion by working together rather than separately.
Conclusions
We have demonstrated that WESS suppresses osteoclast
differentiation by inhibiting RANKL-induced signaling
pathways and decreasing c-Fos protein level and also at-
tenuates bone resorption activity of mature osteoclasts by
disrupting actin ring structure. Our results provide scien-
tific evidence to support the traditional use of S. suberectus
to treat arthritis and suggest that WESS is potentially use-
ful in treating other bone destructive diseases caused by
excessive bone resorption.
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